Hikma Pharmaceuticals Plc (HIK) Given Consensus Recommendation of “Hold” by Brokerages

Hikma Pharmaceuticals Plc (LON:HIK) has been given an average recommendation of “Hold” by the ten analysts that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and two have assigned a buy rating to the company. The average 1-year target price among brokers that have covered the stock in the last year is GBX 1,188.90 ($16.00).

Several research firms recently commented on HIK. Numis Securities reaffirmed a “buy” rating and issued a GBX 1,300 ($17.50) price objective on shares of Hikma Pharmaceuticals in a report on Wednesday, December 20th. Jefferies Group raised their price target on shares of Hikma Pharmaceuticals from GBX 1,045 ($14.06) to GBX 1,074 ($14.45) and gave the company a “hold” rating in a report on Monday, December 4th. Morgan Stanley reissued an “equal weight” rating and issued a GBX 1,100 ($14.80) price target on shares of Hikma Pharmaceuticals in a report on Friday, December 1st. Peel Hunt reissued a “hold” rating and issued a GBX 1,390 ($18.71) price target on shares of Hikma Pharmaceuticals in a report on Wednesday, November 15th. Finally, JPMorgan Chase & Co. cut their price target on shares of Hikma Pharmaceuticals from GBX 1,250 ($16.82) to GBX 1,000 ($13.46) and set a “neutral” rating for the company in a report on Friday, November 10th.

Hikma Pharmaceuticals (LON:HIK) opened at GBX 1,143 ($15.38) on Monday. The stock has a market cap of $2,760.00 and a price-to-earnings ratio of 2,198.08. Hikma Pharmaceuticals has a 1-year low of GBX 906.50 ($12.20) and a 1-year high of GBX 2,346 ($31.57).

COPYRIGHT VIOLATION NOTICE: This news story was posted by Community Financial News and is the property of of Community Financial News. If you are viewing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright and trademark laws. The correct version of this news story can be read at https://www.com-unik.info/2017/12/25/hikma-pharmaceuticals-plc-hik-given-consensus-recommendation-of-hold-by-brokerages.html.

About Hikma Pharmaceuticals

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.

Analyst Recommendations for Hikma Pharmaceuticals (LON:HIK)

Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit